This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Near Patient Molecular Testing in Sepsis

Sponsored by Immunexpress

About this trial

Last updated 8 months ago

Study ID

NEPTUNE IXP-181

Status

Completed

Type

Observational

Placebo

No

Accepting

18-75 Years
18 to 95 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 3 years ago

What is this trial about?

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

What are the participation requirements?

Yes

Inclusion Criteria

1. ≥18 years old on the date of ICU admission

2. Systemic Inflammatory Response Syndrome (SIRS) present, as defined by the presence of two or more of the following:

1. Temperature > 38°C or < 36°C
2. Heart Rate > 90 beat/min
3. Tachypnea > 20/min or PaCO2 < 32 mmHg
4. WBC count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils (bands)

3. Consent to study inclusion, either by patient or legal surrogate before study-related sample processing

4. Study sample collection within 24 hours of ICU admission order

No

Exclusion Criteria

1. Age less than 18 years old on the day of ICU admission

2. No order to admit to ICU

3. Not physically admitted to ICU

4. Commencement of non-prophylactic antibiotics ≥ 24 hours prior to ICU admission

5. Study sample collection > 24 hours from ICU admission order

6. No clinical cultures or serologic tests obtained when sepsis was suspected

7. Elective cardiac surgery patients with an expected duration in ICU of less than 24 hours

8. Transfer from another ICU where subject was admitted for ≥ 24 hours.

Locations

Location

Status